Rh incompatibility is a condition that develops when a pregnant woman has Rh-negative blood and the baby in her womb has Rh-positive blood.
Rh-induced hemolytic disease of the newborn; Erythroblastosis fetalis
Causes, incidence, and risk factors
During pregnancy, red blood cells from the unborn baby can cross into the mother's bloodstream through the placenta.
If the mother is Rh-negative, her immune system treats Rh-positive fetal cells as if they were a foreign substance and makes antibodies against the fetal blood cells. These anti-Rh antibodies may cross back through the placenta into the developing baby and destroy the baby's circulating red blood cells.
When red blood cells are broken down, they make bilirubin. This causes an infant to become yellow (jaundiced). The level of bilirubin in the infant's bloodstream may range from mild to dangerously high.
Because it takes time for the mother to develop antibodies, firstborn infants are often not affected unless the mother had past miscarriages or abortions that sensitized her immune system. However, all children she has afterwards who are also Rh-positive may be affected.
Rh incompatibility develops only when the mother is Rh-negative and the infant is Rh-positive. Thanks to the use of special immune globulins called RhoGHAM, this problem has become uncommon in places that provide access to good prenatal care.
Rh incompatibility can cause symptoms ranging from very mild to deadly. In its mildest form, Rh incompatibility causes the destruction of red blood cells without other effects.
After birth, the infant may have:
- Yellowing of the skin and whites of the eyes (jaundice)
- Low muscle tone (hypotonia) and lethargy
Signs and tests
Before delivery, the mother may have an increased amount of amniotic fluid around her unborn baby (polyhydramnios).
There may be:
- A positive direct Coombs test result
- Higher-than-normal levels of bilirubin in the baby's umbilical cord blood
- Signs of red blood cell destruction in the infant's blood
Because Rh incompatibility is preventable with the use of RhoGAM, prevention remains the best treatment. Treatment of an infant who is already affected depends on the severity of the condition.
Infants with mild Rh incompatibility may be treated with phototherapy using bilirubin lights. IV immune globulin may be used, but there is no conclusive evidence to show it works.
Full recovery is expected for mild Rh incompatibility.
Possible complications include:
- Brain damage due to high levels of bilirubin (kernicterus)
- Fluid buildup and swelling in the baby (hydrops fetalis)
- Problems with mental function, movement, hearing, speech, and seizures
Calling your health care provider
Call your health care provider if you think or know you are pregnant and have not yet seen a doctor.
Rh incompatibility is almost completely preventable. Rh-negative mothers should be followed closely by their obstetricians during pregnancy.
Special immune globulins, called RhoGAM, are now used to prevent RH incompatibility in mothers who are Rh-negative.
If the father of the infant is Rh-positive or if his blood type cannot be confirmed, the mother is given an injection of RhoGAM during the second trimester. If the baby is Rh-positive, the mother will get a second injection within a few days after delivery.
These injections prevent the development of antibodies against Rh-positive blood. However, women with Rh-negative blood type must receive injections:
- During every pregnancy
- If they have a miscarriage or abortion
- After prenatal tests such as amniocentesis and chorionic villus biopsy
- After injury to the abdomen during pregnancy
Alcock GS, Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database of Systematic Reviews 2002, Issue 3. Maheshwari A, Carlo WA. Blood disorders. In: Kliegman RM. Stanton BF, St Gemelll W, Schor NF, Behrman RE,eds. Nelson Textbook of Pediatrics. 19th ed. Philadelphia, Pa: Saunders Elsevier; 2011:chap 97.2.
Reviewed by:Kimberly G Lee, MD, MSc, IBCLC, Associate Professor of Pediatrics, Division of Neonatology, Medical University of South Carolina, Charleston, SC. Review provided by VeriMed Healthcare Network. Also reviewed by A.D.A.M. Health Solutions, Ebix, Inc., Editorial Team: David Zieve, MD, MHA, Bethanne Black, Stephanie Slon, and Nissi Wang.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorousstandards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information andservices. Learn more about A.D.A.M.'s editorialpolicy, editorialprocess, and privacypolicy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch.)
The information provided herein should not be used during any medical emergency or for the diagnosis or treatmentof any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions.Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 2014 A.D.A.M., Inc. Any duplication ordistribution of the information contained herein is strictly prohibited.